Key facts
- It has raised $75.6M; the latest was Later Stage VC in Oct 2025.
- Notable investors include Novo Holdings, Sofinnova Partners, Polaris Partners, EQT Life Sciences, VIB — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Muna Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Muna Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Muna Therapeutics
Operator of a biopharmaceutical company intended to discover neurodegenerative therapies. The company's platform identifies new medicines to preserve cognition and other brain functions and operations resilience to neurodegenerative diseases, including alzheimer's, frontotemporal dementia, and parkinson's, enabling medical companies to help people suffering from neurodegenerative diseases access suitable therapeutics for fast recovery.
- Sector
- Healthcare
- HQ
- Frederiksberg, Denmark
- Founded
- 2020
- Employees
- 23
- Website
- munatherapeutics.com/
- Ownership
- Privately Held (backing)
Muna Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Muna Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Muna Therapeutics in its N-PORT filings yet. We sweep new filings monthly.